To determine and compare the frequency of cancer-associated genetic abnormalities in esophageal metaplasia biopsies with and without goblet cells. Background: Barrett's esophagus is associated with increased risk of esophageal adenocarcinoma (EAC), but the appropriate histologic definition of Barrett's esophagus is debated. Intestinal metaplasia (IM) is defined by the presence of goblet cells whereas nongoblet cell metaplasia (NGM) lacks goblet cells. Both have been implicated in EAC risk but this is controversial. Although IM is known to harbor genetic changes associated with EAC, little is known about NGM. We hypothesized that if NGM and IM infer similar EAC risk, then they would harbor similar genetic aberrations in genes associated with EAC. Methods: Ninety frozen NGM, IM, and normal tissues from 45 subjects were studied. DNA copy number abnormalities were identified using microarrays and fluorescence in situ hybridization. Targeted sequencing of all exons from 20 EAC-associated genes was performed on metaplasia biopsies using Ion AmpliSeq DNA sequencing. Results: Frequent copy number abnormalities targeting cancer-associated genes were found in IM whereas no such changes were observed in NGM. In 1 subject, fluorescence in situ hybridization confirmed loss of CDKN2A and amplification of chromosome 8 in IM but not in a nearby NGM biopsy. Targeted sequencing revealed 11 nonsynonymous mutations in 16 IM samples and 2 mutations in 19 NGM samples.
the marked increase in incidence, death from EAC also continues to rise rapidly. EAC is known to develop through a series of metaplastic, dysplastic, and neoplastic cellular changes that are largely initiated by chronic gastroesophageal reflux disease. 3 Gastroesophageal reflux disease precipitates a metaplastic change of the esophageal epithelium from the normal squamous to a more acid-resistant columnar epithelium known as Barrett's esophagus (BE). BE is estimated to be present in approximately 1.6% 4 of adults in Western populations (up to 4 million Americans), 5, 6 and progression to EAC is estimated to occur in 0.12% to 0.5% of patients per year. 5, [7] [8] [9] Consequently, individuals with BE are recommended to undergo regular endoscopic surveillance with multiple biopsies to identify signs of dysplasia or EAC. 10 The appropriate definition of BE, however, is currently a matter of considerable debate. In the United States, specialized intestinal metaplasia (IM) containing histologically confirmed goblet cells (GCs) is required for a diagnosis of BE 11 whereas in the United Kingdom, the presence of GCs is not currently required for the diagnosis of BE. 12 Historically, the presence of IM has been associated with EAC risk, but recent studies have indicated that metaplasia without GCs (nongoblet cell metaplasia [NGM] ) may also be premalignant and may carry a neoplastic progression risk similar to that of IM. 13, 14 If correct patients with NGM would also be candidates for BE surveillance programs, the cost-effectiveness of which is often criticized given the low rate of progression from BE to cancer. 15, 16 Unfortunately, the cancer-risk of NGM relative to IM remains controversial. 17, 18 One thing that is known, however, is that EAC arises through accumulation of multiple DNA alterations (mutation, DNA copy number abnormality, methylation), many of which are also observed in early dysplastic lesions. [19] [20] [21] Furthermore, IM contains frequent alterations in known cancer-associated genes (TP53, CDKN2A, FHIT, WWOX), 20, 22, 23 and these DNA alterations are presumably the underlying cause for the increased cancer risk associated with IM. 24 On the contrary, very little is known about DNA alterations in NGM, with ploidy changes being the only possible aberrations noted to date. 25 Thus, the goal of this study was to determine and compare the spectrum and frequency of DNA copy number alterations and cancer-associated point mutations in NGM and IM. This was performed on fresh-frozen esophageal biopsy specimens using a combination of Affymetrix SNP 6.0 microarrays, targeted resequencing of cancer-associated genes, and fluorescence in situ hybridization (FISH). underwent upper endoscopy at the University of Rochester Medical Center between 2004 and 2010, and mucosal tissue pieces were obtained from 4 subjects who underwent esophagectomies at the University of Pittsburgh Medical Center between 2003 and 2008. For each subject, the most advanced disease state (EAC > dysplasia > IM > NGM) before or at the time of tissue collection was noted ( Table 1) . All subjects at both institutions provided informed consent, and research was approved by appropriate institutional review boards. Additional information on subjects and specimens is provided in Table 1 .
Specimen Screening
The location of each biopsy/tissue piece was noted as either tubular esophagus or gastroesophageal junction (GEJ) at the time of endoscopy (or on the resection specimen). Specimens were immediately frozen in tissue cassettes containing optimal cutting temperature (OCT) compound to facilitate histologic review. Hematoxylin and eosin-stained sections of each specimen were independently screened by 2 pathologists (Z.Z, K.S). Tissues were classified as NSE, NGM, or IM. IM was defined by the presence of any number of GCs, but GC density was also recorded using a scale of 1 to 3 with 1 = rare GCs, 2 = common GCs, and 3 = numerous GCs (Table 1) . NGM was defined as columnar cell metaplasia without GCs in the entire specimen. NGM was further classified into 2 subgroups of mucosa: oxyntocardiac mucosa (OCM) and cardiac mucosa (CM). OCM consisted of both cardiac and oxyntic glands and CM consisted of only CM without parietal cells (Table 1) .
In some cases, more than 1 biopsy from the same esophageal level (distance from the incisors) was included in a single OCT block. When the histology of these 2 biopsies was different (1 IM and 1 NGM), the tissue block was referred to as being a composite sample (see Supplemental Digital Content Fig. 1C , available at http://links. lww.com/SLA/A517). It is important to note that composite samples consist of 2 separate biopsies that were typically separated by 1 to 2 cm in esophageal location and are thus independent tissue pieces.
Specimen Selection
Specimens were selected for study only if diagnostic consensus was reached between the 2 pathologists and if the sample consisted of more than 70% tissue of interest with less than 30% NSE or submucosa. Furthermore, OCM samples were included only if the endoscopic location was tubular esophagus. OCM samples from the GEJ were excluded to avoid the possibility that they were actually oxyntic mucosa from the stomach. CM (and IM) samples were included from both GEJ and tubular esophagus, as the histologic distinction between CM and oxyntic mucosa from the stomach is more easily made. In all cases, both pathologists were confident that the biopsies included for study represented esophageal metaplasia.
Final Histologic Review and DNA Isolation
Selected specimens were cut on a cryostat (20-30 × 5 μM sections) for DNA isolation. The first, middle, and final sections were placed on slides, H&E stained and reviewed by both pathologists. Genomic DNA was isolated from the intervening tissue sections using the QiaAmp DNA Mini Kit (Qiagen, CA). DNA concentration and purity was assessed by ultraviolet absorbance (NanoDrop 1000; Thermo Fisher Scientific, Waltham, MA), and the DNA quality was assessed by gel electrophoresis.
Genome-wide Human SNP 6.0 Assay
Fifty-eight specimens of NGM, IM, or composite histology were analyzed for DNA copy number abnormalities using the Affymetrix SNP 6.0 GeneChip arrays (Affymetrix Inc, CA). DNA labeling, array hybridization, washing, and staining were carried out according to the standard Genome-Wide Human SNP Assay Kit instructions (Affymetrix Inc. CA) at the SUNY Upstate Medical University microarray core facility (Syracuse, NY).
DNA Copy Number Analysis
Data analysis was performed in Nexus 6.0 Copy number analysis software (BioDiscovery, CA). All samples were normalized to a baseline reference file created using DNA from blood of 15 individuals from a similar subject population. The data were preprocessed and the log2 DNA copy number ratios for each sample were generated for each probe set on the array using the reference files. The SNP-Rank Segmentation algorithm (implemented in Nexus 6.0) was used to segment the data with a minimum requirement of 8 probe sets and a significance threshold P value of 10 −6 . Log2 copy number thresholds for gains and losses were set at +0.15 (∼2.2 copies) and −0.2 (∼1.7 copies), respectively, whereas high-level gains and homozygous loss were set at +0.5 (∼2.8 copies) and −0.8 (∼1.1 copies), respectively.
Fluorescence In Situ Hybridization
For FISH analysis, frozen tissue samples were first formalinfixed and paraffin-embedded, and 4 μM sections were then cut and fixed on positively charged slides. H&E stained sections were reviewed by the pathologists to ensure that the reoriented tissue was the same histology as determined before the genomic studies.
FISH for CDKN2A (9p21.3) loss and chromosome 8 gain was performed in the Department of Cytogenetics FISH Core Facility (University of Rochester Medical Center, NY) using a VP2000 processor (Abbott Molecular, IL) and standard protocols. Probes for CDKN2A with Spectrum Orange label in combination with an internal control centromere 9 (CEP9) with Spectrum Green label (Cat. No: 05J51-001) and centromere 8 (CEP8) with Spectrum Green label (Cat. No: 06J37-018) were purchased from Abbott Molecular (Des Plaines, IL).
FISH Analysis
Manual enumeration of the FISH signals was performed using a Nikon eclipse 80i microscope (Nikon Instruments Inc., NY) and Cytovision software (Leica Microsystems, IL) under 60× oil immersion lens. Signals from overlapping nuclei were not included and at least 100 nuclei per biopsy were counted. The number of CDKN2A and CEP9 signals or the number of CEP8 signals were recorded for each cell nucleus.
Targeted Resequencing of Genes Frequently Mutated in EAC
A subset of metaplasia samples including 19 NGM, 16 IM, and 5 composite tissues (Table 1 ) along with matched NSE specimens were analyzed using targeted resequencing of 20 genes that are frequently somatically mutated in EAC. These 20 genes were identified from a preliminary analysis of whole exome sequencing data on 56 EAC tumor specimens. 26 Targeted resequencing libraries were generated using the Ion AmpliSeq Technology (Life Technologies, CA). Briefly, 1395 PCR amplicons (no longer than 140 bp) were designed to cover all exons from these 20 genes (>90 kb of total DNA) using the Ion AmpliSeq Designer pipeline (Life Technologies, CA). Primers were pooled for 2 multiplex PCR preamplification reactions each with 10 ng of input DNA, using reagents provided by Ion Torrent. After 14 to 16 PCR cycles, the product was partially digested to polish the ends and adapter sequences were added for multiplexing. After an additional 5-cycle library amplification step, the libraries were combined with Ion Sphere particles for clonal amplification using emulsion PCR. The Ion Sphere particles, DNA polymerase and 
Fifty-seven tissues (indicated by specimen IDs; SIDs) from 45 subjects (indicated by patient IDs; PIDs) were included in this study. Sex, subject's highest disease state, specimen location, and consensus tissue type for the metaplastic tissues are listed. Specimens included in the SNP array and Ion AmpliSeq resequencing specimens are indicated along with goblet-cell (GC) score (0 = none, 1 = rare, 2 = common, and 3 = numerous) for each tissue and the NGM subtypes.
CM-OCM indicates mixture of CM and OCM type; Eso, esophagus; HGD, high grade dysplasia;
LGD, low grade dysplasia; N/A, not applicable; PID, patient ID; SID, specimen ID; Y, included in study. sequencing primers were then loaded into Ion AmpliSeq sequencing chips for sequencing on Ion Personal Genome Machine (PGM) sequencer. 27 Raw sequence reads were then processed using the Ion AmpliSeq Software Suite and mapped to the hg19 reference sequence. Sequence data from metaplasia samples were compared with subjectmatched normal DNA to filter sequence polymorphisms and identify variants. Sequence variants were identified using Ion AmpliSeq Variant caller software, followed by manual review using the Integrated Genome Viewer (http://www.broadinstitute.org/igv/).
PCR Amplification and Sanger Sequencing of CDKN2A exon 2
Exon 2 from CDKN2A was PCR-amplified using forward (5 -GACGACAGCTCCGCAGAAGTT-3 ) and reverse primers (5 -TCTGAGCTTTGGAAGCTCTCAGG-3 ) flanking the 5 and 3 ends of the exon 2. The PCR reaction consisted of 1X GC buffer, 0.25 mM each of dNTP mix, 2 μM each of forward and reverse primers, 1.25X of Advantage GC polymerase mix (Cat. No: 639114, Clontech Laboratories, Inc., Mountain View, CA), and 50 ng genomic DNA in a final volume of 20 uL. PCR conditions included an initial hot start at 94 • C for 3 minutes, followed by 40 cycles of denaturation at 94 • C for 30 seconds and annealing/renaturation at 70 • C for 1 minute and with a final hold at 25 • C. Gel electrophoresis was performed on a 2% agarose gel to check for amplified DNA products. PCR products were then purified using ExoSAP-IT (Affymetrix, CA), and sequencing was performed with the PCR primers at Bio Basic Inc. (Markham, Ontario, Canada) on an ABI 3730XL sequencer (Life Technologies, Foster City, CA). Chromatograms were assembled in DNA Baser Sequence Assembler v2 (Heracle BioSoft SRL, http://www.DnaBaser.com), followed by multiple sequence alignment in ClustalW 2.0 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) using the RefSeq entry NM_000077.4 as the reference sequence.
RESULTS

Tissue Pathology
Ninety fresh frozen tissues (82 biopsies and 8 resection specimens) from 45 subjects met all criteria and were included in the study (73 from the tubular esophagus and 17 from the GEJ; * * * * Table  1 ). Pathology review classified the samples as IM (n = 26), NGM (n = 25), composite (n = 6), and NSE (n = 33). Within this tissue set, multiple specimens (n = 21) were obtained from 9 subjects (indicated in Table 1 ) whereas the remaining 69 samples were from independent subjects.
Subject Cohort Characteristics
The subject cohort was predominantly male (39 males vs 6 females), with an average age of 67 years. Before or at the time of biopsy collection for this study, 13 subjects had a diagnosis of EAC, 22 had dysplasia, 9 had nondysplastic IM, and 1 subject had NGM only with no IM found ( Table 1) .
DNA Copy Number Aberrations in NGM and IM
DNA copy number analysis was performed on 25 NGM, 26 IM, and 6 composite specimens. For comparison, we also included previously analyzed data from 36 early-stage (T1) EAC specimens (see Supplemental Digital Content Fig. 2 , available at http://links. lww.com/SLA/A557). 28 The 26 pure IM samples harbored a total of 73 regions of copy number aberrations. The median length of these regions was 667035 bp (range: 29256-28588324 bp). Sixty-four of 73 regions contain a total of 1935 unique genes (see Supplemental Digital  Content Table 1 , available at http://links.lww.com/SLA/A514). Consistent with previous reports, 20,29 recurrent aberrations were observed that target well-known cancer-associated genes (Fig. 1) . These include deletions at 3p14 (FHIT; 54% of samples), 9p21.3 (CDKN2A; 35%), and 16q23.1 (WWOX; 15%), and amplifications at 8q24 (c-MYC; 4%) and 18q11.2 (GATA6; 8%). In addition, other aberrations were observed in IM samples that appear to match those occurring in T1 EAC samples, although the specific genes driving these events are not well defined. These include regional deletions on 4p and 4q, amplification on 5q and deletion on 5p, deletion on 9q, and amplifications on both 10p and 10q (Fig. 1 ).
In the 25 NGM samples, 40 regions of copy number aberrations were observed with a median length of 218086bp (range: 23691-3781221bp). Twenty-nine regions contain a total of 297 unique genes (see Supplemental Digital Content Table 2 , available at http://links.lww.com/SLA/A515 , and Supplemental Digital Content Fig. 2 , available at http://links.lww.com/SLA/A557), none of which seem to have any previous association with EAC. Six recurrent regions were identified, but all have 100% overlap with regions of known copy number variation and, therefore, likely represent copy number polymorphism 30 rather than true aberrations (see Supplemental Digital Content Table 2 , available at http://links.lww.com/SLA/A515). All other changes observed occurred in only 1 sample each.
Comparison of NGM and IM From the Same Subjects
Specimens with different histologies were available for study from 9 subjects. This included 5 subjects (PIDs: 50, 92, 124, 169,188) with both IM and NGM, 1 subject (patient identifier [PID]: 89) with both composite and IM, and 3 subjects (PIDs: 55, 68, and 104) with composite, IM, and NGM. In the 5 subjects with IM and NGM specimens, DNA copy losses were identified at the FHIT locus in 4 cases, at the CDKN2A locus in 3 cases, and at the WWOX locus in 1 case. In all 5 subjects, these losses were observed in the IM sample only and not in the matched NGM sample (see Supplemental Digital Content Fig. 3 , available at http://links.lww.com/SLA/A526). In subject 89, losses at the FHIT and WWOX genes were observed in the IM sample in addition to losses on chromosomes 5 and 10, but no changes were seen in the composite sample (see Supplemental Digital Content Fig. 3 , available at http://links.lww.com/SLA/A526).
In the 3 subjects with IM, NGM, and composite samples, multiple DNA copy losses and gains were identified in IM and composite samples but not in the NGM samples. For subject 68, loss was observed at the CDKN2A locus in the IM and composite samples but not in the NGM sample. Based on the boundaries of the deleted region, the loss in these 2 tissues seems to be clonally related. However, the composite sample also has an amplification event on chromosome 15 that is not observed in the IM or NGM samples. Similarly, for subject 104, clonally appearing losses of FHIT, chromosome 9 (including CDKN2A but also in other regions), and chromosome 18 were found in the IM and composite samples but not in the NGM sample. Chromosome 10, on the contrary, had multiple regions of loss in the IM sample but regions of gain in the composite, indicating some clonal divergence. Finally, subject 55 had a loss of CDKN2A in both IM and composite samples in addition to a gain of whole chromosome 8 and FHIT loss only in the composite sample (see Supplemental Digital Content Fig. 3 , available at http://links.lww.com/SLA/A526).
For tissues from subject 55, we used FISH to determine whether the alterations observed in the composite sample (UR159) were present in the IM or the NGM biopsy. The SNP array results from the composite specimen (UR159) of subject 55 indicate a gain of chromosome 8 and loss at the CDKN2A locus on chromosome 9 ( Fig. 2A) . The FISH results clearly show that both of these events are present only in the IM biopsy of the composite sample. For the chromosome 8 amplification, 60% of nuclei in the NGM portion had 2 copies of CEP8, 39% had 1 copy, and 1% had 3 copies. This is almost identical to the control NSE sample (see Supplemental Digital Content Fig.  4 , available at http://links.lww.com/SLA/A527). However, in the IM biopsy, 63% of nuclei had 2 copies and 15% had 1 copy whereas 22% had 3 or more copies of CEP8. For CDKN2A/CEP9, 94% of nuclei in the NGM biopsy had 2 copies of both CDKN2A and CEP9 whereas 6% had 2 copies of CEP9 and 1 copy of CDKN2A. In the IM biopsy, 52% of nuclei had 2 copies each of CDKN2A and CEP9 and 7% had 2 copies of CEP9 and 1 copy of CDKN2A whereas 36% had 2 copies of CEP9 but no copies (homozygous deletion) of CDKN2A (Fig. 2 ).
Targeted Resequencing of Frequently Mutated EAC Genes in NGM and IM
To identify cancer-associated point mutations in NGM and IM, we used a highly multiplexed PCR amplification approach to resequence 20 genes that are frequently mutated in EAC on the basis of an interim analysis of an emerging study of the spectrum of mutations in this disease. This focused sequencing was performed for 19 NGM, 16 IM, and 5 composite samples along with their matched normal samples. This analysis revealed a total of 16 nonsynonymous (amino acid modifying) and 5 synonymous (no change to the amino acid) mutations (indicated in Fig. 3 ). Two of these changes were observed in independent NGM samples (2/19; 10.5%) and both were nonsynonymous mutations (in CDKN2A and COL11A1). A total of 14 mutations were observed in the IM samples. Eleven of these were nonsynonymous changes that occurred in 9 (53%) independent samples, with 2 samples each having mutations in 2 different genes. The genes with nonsynonymous mutations in the IM samples were TP53 (n = 4; 25%), SMARCA4 (n = 2; 13%), LRP1B (n = 3; 19%), ERBB2 (n = 1; 6%), and CDKN2A (n = 1, identified by Sanger sequencing; 6%). Finally, 3 nonsynonymous mutations were identified in the composite samples including a mutation in APC in one sample and mutations in ERBB2 and LRPB1 in another sample (sample UR286 from subject 89) ( Fig. 3) . Interestingly, the IM sample (UR289) from the same Targeted resequencing of 20 frequently mutated EAC genes from preneoplastic biopsies. Nineteen NGM, 5 composites, and 16 IM specimens from 36 subjects were analyzed along with matched normal squamous mucosa. Mutations in the coding regions within the specific genes are indicated in red (nonsynonymous mutation) and green (silent substitutions) whereas "C" indicates that the mutation is reported in the COSMIC database and "S" indicates that the point mutation was identified by Sanger sequencing.
subject had identical ERBB2 and LRPB1 mutations indicating clonality. Furthermore, the mutant fraction observed in the IM sample was almost exactly double that was seen in the composite for both mutations.
Mutation Load Discriminates Between Metaplasia and EAC
Detecting progression of metaplasia to EAC (or dysplasia) is the goal of surveillance in subjects with BE. Therefore, we evaluated the discriminatory capacity of mutation load (number of mutations per sample in the 20-gene panel) to detect this event. Data from whole exome sequencing of 66 EAC samples were used for this analysis along with the targeted resequencing data from metaplasia samples. A pairwise receiver-operator characteristic analysis resulted in an area under the curve of 0.954 for any metaplasia (NGM or IM) versus EAC and 0.915 for IM alone versus EAC (Fig. 4) . Thus, mutation load seems to have good potential for detecting disease progression in subjects with BE, and this approach may be applied to esophageal cytology samples and biopsies.
DISCUSSION
These data report the largest and most comprehensive comparison of cancer-associated genetic changes in NGM and IM. We have carefully controlled the collection, preparation, and histologic characterization of the specimens. The location of biopsies with respect to the GEJ was carefully noted, tissues were snap frozen in OCT to facilitate sectioning, and histologic analysis and multiple sections of the same specimen used for DNA isolation were examined independently by 2 pathologists. We identified numerous genetic changes in IM epithelium using high-resolution DNA copy number analysis of the whole genome. These findings are in agreement with previous studies and reveal that the changes frequently target wellknown cancer-associated genes and regions that are similarly altered in early-stage EAC. In contrast, we found far fewer DNA copy number changes in NGM. When present in NGM, abnormalities were commonly in regions with established copy number polymorphisms, were smaller than those in IM, and often did not contain any known genes. Furthermore, when analyzing multiple tissues from the same subject, IM samples were found to have copy number changes whereas the matched NGM samples did not. This was true for at least 1 subject in which NGM and IM biopsies from the same level (distance from the incisors) were analyzed using FISH. In these tissues, chromosome 8 gain and CDKN2A loss were found only in the IM biopsy and not in the adjacent NGM biopsy.
We further refined the findings with targeted resequencing of the entire coding region of 20 cancer-associated genes frequently mutated in EAC. This was achieved using novel technology (AmpliSeq) capable of assembling customized next-generation sequencing libraries starting with very low DNA input. Eleven nonsynonymous mutations in 16 IM samples were identified including mutations in the TP53 and CDKN2A genes as previously reported. We also identified nonsynonymous mutations in other cancer-associated genes not previously reported, including ERBB2, SMARCA4, and LRP1B. Many of the observed mutations in IM tissues are present in the COSMIC database, indicating that they may be drivers of cancer risk. As with DNA copy number changes, point mutations in NGM were much less common than in IM, with only 2 of 19 samples each having a single mutation. Interestingly, one of these mutations was in the CDKN2A gene, and this specific mutation is also in the COSMIC database. Taken together, these data show that NGM harbors far fewer cancerassociated genetic aberrations than IM. This was true although the NGM samples were collected from an extremely "high-risk" cohort of subjects with most having coincident dysplasia or EAC.
Because the recognition of the columnar-lined esophagus in the 1950s and subsequent studies drawing a link between metaplastic esophageal epithelium and EAC, the diagnosis of BE has become synonymous with risk of developing EAC. It is now recognized that esophageal columnar metaplasia is not a simple or single entity but can be classified into a variety of subtypes depending on the type and distribution of specific cell types (eg, parietal cells, chief cells, mucous cells, GCs, Paneth cells, and pancreatic acinar cells) and/or the presence and structure of submucosal glands. Among these, the presence or absence of GCs has emerged as the most clinically relevant, as it identifies IM, currently required for the definition of BE in the United States and many other countries. The diagnosis of BE triggers recommendations to enter endoscopic surveillance programs aimed at detecting progression to dysplasia or EAC. Of significance, the requirement for presence of GCs in the definition has recently been challenged as a result of studies implicating nongoblet cell metaplasia (NGM) in the development of EAC (reviewed by Riddell and Odze 18 ). The requirement of the GC to define BE, and its inferred cancer risk, remains a highly controversial topic and one that carries major clinical and economic implications.
Cancer develops as a result of genetic abnormalities that drive transformation and progression. Numerous studies have also shown the presence of genetic changes (mutation, DNA copy number changes, methylation, etc) in samples of IM. 20, 22, 29 These include changes in well-known cancer genes including TP53, CDKN2A/p16, APC, SMAD4, FHIT, and WWOX. Many of these changes have also been associated with a markedly increased risk of progression to dysplasia or EAC. 19, 31, 32 Specifically, loss or mutation of TP53 and CDKN2A, aneuploidy, and the extent of clonal diversity observed in IM are all generally accepted biomarkers for increased risk of progression. 3, 19, 24 In contrast, only 1 study has specifically analyzed DNA changes in NGM. 25 DNA content abnormalities, DNA heterogeneity index, DNA exceeding 5N, and aneuploidy were reported to occur with equal frequency and extent in NGM and BE. In another study, Chaves and colleagues 33 reported that gains of chromosome 7 and 18 are more common in GCs than in columnar cells. Although this study has been quoted as evidence for genetic abnormalities in NGM, 18 it should be noted that all specimens used in the study by Chaves and colleagues were clearly described as being IM. As such, this study does not globally identify changes in NGM but rather shows that at the cellular level within intestinalized epithelia (IM), the frequency of genetic changes is lower in the GCs than in the surrounding columnar cells. These reports represent what is very limited data on the genetic abnormalities present in NGM epithelia.
CONCLUSIONS
Genomic analyses of the scale performed here are currently not economically feasible for clinical testing, particularly considering the need for multiple biopsies performed every 1 to 2 years, nor do they address the issue of sampling error. It is feasible, however, that adding genetic analysis to the recently reported use of a Cytosponge 34, 35 to collect esophageal cytology specimens may prove clinically useful. For example, given the identification of IM via a screening cytology analysis, a paired mutation analysis could provide a baseline estimate of progression risk (regardless of IM or NGM status). Abnormal cytology or a high incidence of mutations could also trigger endoscopy. Repeat cytology samples could be collected and mutation analysis used to detect/monitor (not predict) progression from baseline and triage subjects to endoscopy. Even with the limited set of 20 genes analyzed, our data clearly show that mutation load can differentiate metaplasia from EAC. Additional studies would be required to identify an optimal gene panel, evaluate mutation load in dysplasia, and develop appropriate classification algorithms. Next-generation sequencing technologies are perfect for this type of test as they are capable of detecting very rare mutation events in the large background of normal cell DNA present in cytology specimens. Furthermore, the 20-gene assay presented here was designed (and has been tested) to work on highly fragmented DNA such as that obtained from routinely fixed and processed clinical specimens. Perhaps the question to ask when determining effective management strategies for subjects with esophageal columnar metaplasia should no longer be the presence or absence of GCs but rather the spectrum and frequency of mutations present in each individual case.
